Navigation Links
Optimer Pharmaceuticals' Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Date:8/19/2010

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the European Medicines Agency (EMA) has accepted for review Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI in the European Union (EU).  Optimer announced the submission of its MAA for fidaxomicin to the EMA on August 2, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"An independent survey recently conducted by Decision Resources indicates that CDI is on the rise and that nearly 70% of surveyed infectious disease specialists and internists would use fidaxomicin in first- and second-line treatment of CDI, if approved," said Pedro Lichtinger, President and CEO of Optimer. "We believe the potential demand for a narrow spectrum antibiotic with lower recurrence rates for the treatment of CDI is significant. The acceptance for review of the fidaxomicin marketing application by the EMA is an important step in bringing this much needed therapy to Europe, where treatment options are limited.  With the validation of this MAA, we believe we have significantly improved the risk profile of our European program that when combined with our growing excitement and understanding of CDI incidence, access and prescribing intentions across the region, present an enhanced value proposition for fidaxomicin."  

Given these developments, the Company is increasing its focus on its European partnering process for fidaxomicin. J.P. Morgan has been engaged to advise and assist Optime
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
(Date:5/17/2013)... DIEGO , May 17, 2013  Orexigen® Therapeutics, Inc. ... present a company overview at the UBS Global Healthcare Conference ... scheduled for Wednesday, May 22 nd at 11 a.m. ... replay of the presentation, please visit the Investor Relations section ... replay will be available for 14 days after the event. ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- United Medical Education, a ... Support (ACLS), Pediatric Advanced Life Support (PALS) and Basic ... and ACLS online course manuals. In order ... need to build an account with the company. By ... programs, United Medical Education is setting a precedent among ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2
... 8, 2010 Reportlinker.com announces that a new ... Monoclonal Antibodies: 2010 ... the branded prescription pharmaceutical market monoclonal antibodies (MAbs) ... type, delivering a forecast six year compound annual ...
... 2010 Reportlinker.com announces that a new market ... Prostate Cancer - Spain Drug Forecasts ... http://www.reportlinker.com/p0332354/Prostate-Cancer---Spain-Drug-Forecasts-and-Treatment-Analysis-to-2020.html Prostate Cancer ... 2020 SummaryGlobalData,s pharmaceutical report, "Prostate ...
Cached Medicine Technology:Reportlinker Adds Monoclonal Antibodies: 2010 2Reportlinker Adds Monoclonal Antibodies: 2010 3Reportlinker Adds Monoclonal Antibodies: 2010 4Reportlinker Adds Monoclonal Antibodies: 2010 5Reportlinker Adds Monoclonal Antibodies: 2010 6Reportlinker Adds Monoclonal Antibodies: 2010 7Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 14
(Date:5/19/2013)... OH (PRWEB) May 19, 2013 The ... continue to follow developments in the nation’s first trial ... case, underway in Washington State Superior Court, was filed ... years after he suffered complications in a robot-assisted prostate ... The Da Vinci robotic surgery lawsuit alleges ...
(Date:5/18/2013)... MAY 19, 2013 The American Society for ... field of endoscopy during the ninth annual ASGE Crystal ... and the ASGE Foundation, this year,s event will begin ... in Orlando, Fla. , Held in conjunction with ... the finest in leadership, research and scientific pursuit. The ...
(Date:5/18/2013)... Online watch retailer Time and Gems is offering shoppers ... a fraction of its usual cost. With great deals on ... are urged to take advantage of Time and Gems’ wholesale ... a brick-and-mortar store, buyers now have the option of buying ... rates. Although some buyers may have qualms about buying luxury ...
(Date:5/18/2013)... few extra cups of coffee each month might help ... as primary sclerosing cholangitis (PSC), a new study suggests. ... found that drinking coffee was associated with a reduced ... cirrhosis of the liver, liver failure and biliary cancer. ... "While rare, PSC has extremely detrimental effects," ...
(Date:5/18/2013)... -- Regular consumption of coffee is associated with ... an autoimmune liver disease, Mayo Clinic research shows. ... Disease Week 2013 conference in Orlando, Fla. ... bile ducts that results in inflammation and subsequent ... liver, liver failure and biliary cancer. , "While ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2
... growing epidemic of the world,s most common heart rhythm ... admissions in Australia, according to cardiology researchers. A ... University of Adelaide and the Cardiovascular Research Centre at ... to atrial fibrillation had more than tripled in Australia ...
... Elsevier, a world-leading publisher of scientific, technical ... the launch of SciVerse, an innovative platform that ... scientific community to collaborate on the development of ... to releasing the APIs (application programming interfaces) for ...
... available in French . The medicinal use ... the public at large for many years as an alternative ... be effective and may have unwanted side effects. A new ... researchers provides evidence that cannabis may offer relief to patients ...
... , SUNDAY, Aug. 29 (HealthDay News) -- Having a particular ... risk of getting migraines, new research shows. While migraines ... specific genes has proven difficult, the researchers said. The ... genetic variant associated with a heightened risk for the most ...
... cannabis reduces pain, improves mood and helps sleep, ... Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj091414.pdf ... pain due to damage or dysfunction of the ... include opioids, anticonvulsants, antidepressants and local anesthetics, but ...
... Portugal: Many children are being put at risk by ... fever, coughs and colds, says a study from Australia to ... Federation (FIP) today (Monday 30 August). The ... Sydney, New South Wales, say that dosing errors and inappropriate ...
Cached Medicine News:Health News:Heart disorder hits national epidemic proportions 2Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:Smoked cannabis reduces chronic pain 2Health News:Widespread parental misuse of medicines puts children at risk 2Health News:Widespread parental misuse of medicines puts children at risk 3
Using the patient's own blood pressure as the driving force, CAVR circulates cold blood through the Level 1 heat exchanger and returns it to the patient at body temperature for rapid core rewarming....
... HOTLINE can deliver normothermic fluid to your ... HOTLINE tubing design surrounds the patient line ... eliminating patient line cool down. The HOTLINE ... position, requires less priming volume, and is ...
... control panel is conveniently located on the swivel ... whether standing or sitting. The ventilator control panel ... numerics. The ventilator has CMV, PCV and SIME ... in two lengths facilitates both the placing of ...
... provides high quality ventilation and monitoring ... technologies of the AV2+ ventilator, breathing ... GS user-friendly and intuitive. , ... GS is the perfect introduction to ...
Medicine Products: